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AbstrAct
Background In patients with ischaemic left ventricular 
dysfunction, coronary artery bypass surgery (CABG) may 
decrease mortality, but it is not known whether CABG 
improves functional capacity.
Objective To determine whether CABG compared with 
medical therapy alone (MED) increases 6 min walk 
distance in patients with ischaemic left ventricular 
dysfunction and coronary artery disease amenable to 
revascularisation.
Methods The Surgical Treatment in Ischemic Heart 
disease trial randomised 1212 patients with ischaemic 
left ventricular dysfunction to CABG or MED. A 6 min walk 
distance test was performed both at baseline and at least 
one follow-up assessment at 4, 12, 24 and/or 36 months 
in 409 patients randomised to CABG and 466 to MED. 
Change in 6 min walk distance between baseline and 
follow-up were compared by treatment allocation.
Results 6 min walk distance at baseline for CABG was 
mean 340±117 m and for MED 339±118 m. Change in 
walk distance from baseline was similar for CABG and 
MED groups at 4 months (mean +38 vs +28 m), 12 months 
(+47 vs +36 m), 24 months (+31 vs +34 m) and 36 months 
(−7 vs +7 m), P>0.10 for all. Change in walk distance 
between CABG and MED groups over all assessments was 
also similar after adjusting for covariates and imputation 
for missing values (+8 m, 95% CI −7 to 23 m, P=0.29). 
Results were consistent for subgroups defined by angina, 
New York Heart Association class ≥3, left ventricular 
ejection fraction, baseline walk distance and geographic 
region.
Conclusion In patients with ischaemic left ventricular 
dysfunction CABG compared with MED alone is known 
to reduce mortality but is unlikely to result in a clinically 
significant improvement in functional capacity.
Trial registration number NCT00023595.
InTROduCTIOn
In patients with coronary heart disease and 
heart failure, exercise capacity is an important 
determinant of quality of life and a powerful 
predictor of mortality.1 Coronary revascular-
isation has the potential to improve exercise 
capacity by relieving ischaemic symptoms 
during exercise or decreasing cardiac dysfunc-
tion related to myocardial ischemia. However, 
previous trials have not demonstrated a clear 
improvement in functional capacity after 
coronary artery revascularisation compared 
with medical therapy (MED) alone. In the 
COURAGE trial, the largest randomised trial 
comparing percutaneous coronary interven-
tion (PCI) with MED in patients with stable 
coronary heart disease, the PCI strategy 
resulted in a modest improvement in angina 
during the first 12 months, but no improve-
ment in physical function assessed by ques-
tionnaire at or after 12 months.2 Smaller 
Key messages
What is already known about this subject?
In previous clinical trials, functional capacity did 
not improve in patients with stable coronary artery 
disease after coronary revascularisation compared 
with medical therapy alone. However, no trials have 
evaluated effects of coronary artery bypass surgery 
(CABG) on an objective test of exercise capacity in 
patients with ischaemic left ventricular dysfunction.
What does this study add?
In this analysis from the Surgical Treatment in Ischemic 
Heart disease trial, 6 min walk distance was similar 
during 3-year follow-up for patients randomised to 
CABG and to medical therapy alone.
How might this impact on clinical practice?
In patients with ischaemic left ventricular dysfunction, 
CABG may be indicated to improve survival but is 
unlikely to improve functional capacity.
group.bmj.com on March 9, 2018 - Published by http://openheart.bmj.com/Downloaded from 
Open Heart
2 Stewart RAH, et al. Open Heart 2018;5:e000752. doi:10.1136/openhrt-2017-000752
randomised trials have also not demonstrated sustained 
improvement in functional capacity with coronary revascu-
larisation in patients with stable coronary artery disease.3 In 
the more recent ORBITA trial, there was no difference in 
angina or functional capacity in patients with angina and 
single vessel coronary artery disease who were randomised 
to PCI or a sham procedure.4 
The Surgical Treatment for Ischemic Heart Failure 
(STICH) trial is the only large randomised trial to 
compare coronary artery bypass surgery (CABG) with 
optimal MED in patients with severe left ventricular (LV) 
dysfunction who have coronary artery disease amenable 
to revascularisation.5 During a median follow-up of ~10 
years, patients randomised to CABG had lower all-cause 
and cardiovascular mortality compared with those 
randomised to optimal MED.6 Compared with patients 
with normal LV function, functional capacity is more 
likely to be limited in those with ischaemic LV dysfunc-
tion, and these patients could also have a greater poten-
tial to improve with revascularisation. We previously 
reported that baseline 6 min walk (6 MW) distance 
predicted mortality during follow-up in the STICH trial.7 
The aim of this analysis was to determine whether CABG 
compared with MED alone increases 6 MW distance 
during follow-up in STICH trial participants.
MeTHOds
Patient population
The STICH trial randomised 1212 patients with an LV 
ejection fraction of 35% or less and coronary artery 
disease suitable for revascularisation to either CABG and 
optimal MED or to MED alone.5 6 Optimal MED included 
ACE inhibitor and/or angiotensin receptor blocker, a 
β-blocker, an aldosterone antagonist and antiplatelet 
agents adjusted to optimal doses. Statins, diuretics and 
digitalis were individualised to patient-specific indica-
tions. The use of implantable defibrillators was encour-
aged. Patients were enrolled at 99 clinical sites in 22 coun-
tries between July 2002 and May 2007. The rationale, trial 
design and complete inclusion and exclusion criteria 
have been described previously.8 All patients provided 
written informed consent.
six-minute walk
The trial protocol included a 6 MW test for all able study 
participants at baseline and the 4-month, 12-month, 
24-month and 36-month follow-up assessments. The walk 
test was usually performed with distance marked in a 
long corridor free of obstacles. Instructions to patients 
included, ‘Walk for 6 min around this course, covering as 
much ground as possible during that time. Keep going 
continuously, if possible, but don’t worry if you have 
to slow down and rest’. Subjects were included in the 
current analysis if they completed both the baseline and 
at least one follow-up walk test (figure 1).
statistical analysis
All primary comparisons were performed with the treat-
ment group defined according to the intention-to-treat 
principle. Descriptive statistics included counts (percent-
ages) for categorical variables and medians (25th and 
75th percentiles) or means with SD for continuous vari-
ables. The Pearson’s χ2 test was used for categorical vari-
able comparisons. Changes in 6 MW distance from base-
line to each follow-up time (4, 12, 24 and 36 months) 
were reported both as mean±SD, and median and 25% 
and 75% centiles.
Treatment comparisons were also evaluated using 
a linear mixed-effects model to account for repeated 
measures within a patient.  In PROC MIXED in SAS, 
V.9.4, the baseline, 4-month, 12-month, 24-month and 
36-month measurements for a patient were fitted using 
maximum likelihood methods with unstructured cova-
riance matrix.9 This analysis included imputations for 
missing values for patients who were hospitalised at that 
time point or had died. For hospitalised patients, the 
worst non-null walk distance collected across the study 
was assigned. For patients who died, a value of 0 was used. 
At each time point, estimated treatment differences, 95% 
CI and P values were obtained using the model estimates. 
All reported P values were two sided. No adjustment was 
made in significance levels for multiple comparisons.
The difference in walk distances between baseline and 
12 months are reported for subgroups defined for the 
primary analysis of the Surgical Treatment for Ischemic 
Heart Failure Extension Study (STICHES) trial.6 Results 
are also reported for patients with a Kansas City Cardio-
myopathy Questionnaire (KCCQ) score10 and physical 
activity score7 above compared with below the median for 
the trial population.
ResulTs
Eight hundred seventy-five STICH trial patients (72%) 
who completed the 6 MW test at baseline and at least one 
follow-up assessment were included in this analysis. For 
these subjects, clinical characteristics were similar for those 
randomised to CABG (409, 67%) and MED (466, 77%) 
(table 1). Reasons for non-performance of the walk test at 
baseline and during follow-up are displayed by treatment 
allocation in figure 1.
6 MW distance was similar for subjects randomised to 
CABG compared with MED at baseline. For both groups, 
there was a modest increase in walk distance between 
baseline and 4, 12 and 24 months. Walk distance at 
36 months was similar to baseline. The decrease in walk 
distance from 12 and 24 months to 36 months was greater 
for the 25th centiles compared with the medians and the 
75th centiles, suggesting the temporal change reflected 
an increase in the number of subjects with a low walk 
distance (figure 2). The changes in walk distance between 
baseline and each follow-up assessment were similar by 
treatment allocation (table 2).
In a repeated measures model that evaluated all visits, 
and with imputation for missing values, walk distance 
increased more for subjects randomised to CABG 
compared with MED only (difference +35 m, 95% CI 20 m 
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Figure 1 Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each 
follow-up time are given. CABG, coronary artery bypass surgery; STICH, Surgical Treatment for Ischemic Heart Failure.
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to 51 m, P<0.001). After also adjustment for covariates 
(baseline distance walked, treatment received, age, LV 
end systolic volume index, history of stroke, creatinine, 
moderate severe MR and pulse rate) the change in walk 
distance averaged across all assessments was similar for 
CABG and MED groups, respectively (difference +8 m, 
95% CI −7 m to 23 m, P=0.29).
Change in walk distance at 12-month follow-up in 
subgroups are displayed in the forest plot (figure 3). There 
was a nominally significant interaction between race/
ethnic group and increase in walk distance with CABG 
compared with MED alone. There were no other statisti-
cally significant interactions for difference in walk distance 
by treatment allocation for other baseline characteristics.
To determine whether change in 6 MW was prognos-
tically important, the association between increases in 
6 MW compared with baseline was determined for 10-year 
mortality. The HR for death for each 10 m increase in 
6 MW between baseline and 4 months was 0.997 (95% CI 
0.988 to 1.006), P=0.47, 12 months 0.984 (0.971 to 0.997), 
P=0.0018, 24 months 0.983 (0.973 to 0.994), P=0.002, and 
at 36 months 0.989 (0.981 to 0.998), P=0.022.
dIsCussIOn
In this analysis from the STICH trial, there was no 
clinically important difference in 6 MW distance over 
3 years for patients randomised to CABG compared 
with optimal MED alone. Trends for the 25th and 75th 
centiles by treatment group were similar to the median, 
suggesting ‘average’ changes were not masking a substan-
tial improvement for some patients and worsening for 
others. Also subgroup analyses did not identify clinical 
features associated with a greater likelihood of improve-
ment in walk distance with CABG. The difference in walk 
distance by treatment group were less than the minimally 
clinically evident change estimated from previous studies 
at ~25 m in coronary heart disease rehabilitation,11 ~44 m 
in pulmonary hypertension 12 and between 30 m and 
50 m in heart failure trials.13
These observations are consistent with the absence of a 
clinically significant improvement in functional capacity 
after revascularisation, compared with MED only, 
reported in previous clinical trials of patients with stable 
coronary heart disease but without severe impairment of 
Table 1 Baseline characteristics for study participants randomised to CABG and optimal medical therapy (MED) and to 
optimal MED
Baseline characteristics All patients MED CABG P value
Number of subjects 875 466 409 0.70
Age (years) Mean±SD 60.0±9.0 60.0±9.2 60.0±8.7 0.66
Male, n (%) 774 (88.5) 412 (88.4) 362 (88.5) 0.97
Region of enrolment, n (%) 0.80
  Poland 273 (31.2) 145 (31.1) 128 (31.3)
  USA/Canada 151 (17.3) 83 (17.8) 68 (16.6)
  West Europe 73 (8.3) 42 (9.0) 31 (7.6)
  Other 378 (43.2) 196 (42.1) 182 (44.5)
Ethnic minority, n (%) 270 (30.9) 138 (29.6) 132 (32.3) 0.40
Hyperlipidaemia, n (%) 526 (60.2) 285 (61.3) 241 (58.9) 0.48
Hypertension, n (%) 527 (60.2) 285 (61.2) 242 (59.2) 0.55
Diabetes, n (%) 344 (39.3) 189 (40.6) 155 (37.9) 0.42
Peripheral vascular disease, n (%) 117 (13.4) 70 (15.0) 47 (11.5) 0.13
Chronic renal insufficiency, n (%) 44 (5.0) 25 (5.4) 19 (4.7) 0.63
Atrial fibrillation/flutter, n (%) 105 (12.0) 59 (12.7) 46 (11.2) 0.52
Current smoker, n (%) 169 (19.3) 91 (19.6) 78 (19.1) 0.85
Depression, n (%) 42 (4.8) 20 (4.3) 22 (5.4) 0.45
Current angina class ≥II, n (%) 412 (72.7) 219 (73.7) 193 (71.5) 0.55
Current NYHA ≥III, n (%) 283 (32.3) 155 (33.3) 128 (31.3) 0.54
BMI (kg/m2) 27.4±4.6 27.4±4.7 27.4±4.5 0.85
LVEF (%) 28.3±8.9 28.6±9.1 27.9±8.7 0.41
LV end systolic volume index 85.7±36.3 87.1±37.5 84.1±34.9 0.30
Moderate-severe mitral regurgitation, n (%) 157 (18.0) 92 (19.8) 65 (15.9) 0.14
Three vessel/stenosis ≥75%, n (%) 304 (34.7) 156 (33.5) 148 (36.2) 0.40
Physical activity score* 71 (50.0, 88.0) 71 (50.0, 88.0) 71 (50.0, 88.0) 0.45
KCCQ score 64 (47.0, 80.0) 63.5 (47.0, 82.0) 64 (47.0, 79.0) 0.65
*Median (25th and 75th).
6 MW, 6 min walk; BMI, body mass index; CABG, coronary artery bypass grafting;  KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, 
left ventricular; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; STICH, Surgical Treatment 
for Ischemic Heart Failure trial.
group.bmj.com on March 9, 2018 - Published by http://openheart.bmj.com/Downloaded from 
5Stewart RAH, et al. Open Heart 2018;5:e000752. doi:10.1136/openhrt-2017-000752
Coronary artery disease
LV function.2 3 In the COURAGE trial, which randomised 
patients with stable CHD to either PCI or MED, there was 
a modest improvement in angina at 12 months, but not at 
24 or 36 months, and no difference in functional capacity 
or quality of life by treatment allocation.2 Similar obser-
vations were reported from a meta-analyses that included 
additional smaller studies comparing coronary revascu-
larisation to MED alone in patients with stable coronary 
heart disease.3
CABG could have a greater potential to improve 
exercise capacity in patients with angina, myocardial 
ischaemia or viable myocardium. However, STICH trial 
patients with angina compared with those without angina 
were not more likely to increase their 6 MW distance 
after CABG. Also previous subgroup analyses from 
STICH reported no difference in outcomes from CABG 
compared with MED by presence of angina,14 myocar-
dial viability15 or myocardial ischaemia16 at baseline. 
Previous analyses from STICH have reported a small but 
statistically significant improvement in quality of life with 
CABG compared with MED17 and a modest decrease in 
angina (50% with CABG vs 41% with MED).14 A limita-
tion of questionnaire-based assessment of quality of life, 
compared with more objective measures, is that responses 
may be influenced by knowledge of cardiac disease.18 In 
the ORBITA trial, which included a sham procedure, 
there was no significant improvement in exercise time or 
quality of life after PCI in patients with angina and single 
vessel coronary artery disease.4
We previously reported that baseline 6 MW distance 
predicted all-cause mortality after adjusting for other 
covariates.7 In the current analysis, we also report that 
both increase and decrease in 6 MW distance between 
baseline and 1 year are also associated with mortality 
risk. These observations suggest that functional capacity 
assessed by the 6 MW test is prognostically important in 
this study population. We also previously reported that 
patients who walked <300 m or had lower levels of phys-
ical activity assessed by questionnaire did not have a clear 
mortality benefit from CABG compared with those with 
greater exercise capacity.7 Knowledge that these patients 
also are unlikely to have an improvement in functional 
capacity from CABG compared with MED is important 
when considering the benefits of CABG in individual 
patients.
In the STICH trial, mortality was lower after a 10-year 
follow-up in patients randomised to CABG, with mortality 
benefit accruing gradually over time. At 1-year mortality 
Figure 2 Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to 
medical therapy alone. The median change and 25th and 75th percentiles are displayed. Differences by treatment group were 
not statistically significant at any time. CABG, coronary artery bypass surgery.
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was nominally higher after CABG.6 The small favourable 
effect of CABG on angina and quality of life reported 
previously were greatest at 1 year and less at 2-year and 
3-year follow-up.17 In the current analysis, most data on 
6 MW distance was available at 1 year, and assessments 
were only made to year 3. The results and timing of 
assessments in this study suggest the long-term survival 
benefit from CABG compared with MED in patients with 
ischaemic LV dysfunction are independent of changes in 
functional capacity.
study limitations
Baseline characteristics for patients included in the 
analysis were similar by treatment allocation, but fewer 
patients randomised to CABG completed the base-
line walk test, and more patients randomised to MED 
compared with CABG had missing tests during follow-up, 
in part because of higher mortality. The reasons for base-
line differences in completion of the 6 MW are uncertain. 
It is possible that imbalances in missing tests by treatment 
group resulted in a survival bias. This was evaluated in a 
sensitivity analysis with imputation of ‘0’ walk distance for 
patients who died, and the lowest reported walk distance 
for missing tests. Because slightly more patients in the 
MED group died during follow-up, these imputed values 
may underestimate 6 MW distance during follow-up for 
MED relatively more than the CABG group.
Walk distance is influenced by the motivation of the 
patient and the person supervising the test. These factors 
may have contributed to substantial variation in walk 
distance between assessments, and this decreases the 
value of the walk test for assessing change in functional 
capacity in individual patients. However, between tests, 
variation was similar for both randomised groups, and 
the 95% CIs exclude clinically important differences in 
average walk distance between treatment groups. During 
the first year of follow-up, ~10% of subjects randomised 
to MED cross over to CABG, which may act to decrease 
estimates of any benefits of CABG on functional capacity. 
The study was undertaken in many countries that may 
have different levels of medical or access to different ther-
apies, but results were broadly similar across geographic 
regions. Randomisation and the intention-to-treat anal-
ysis would result in balancing of these and other unmea-
sured factors by treatment allocation.
The 6 MW test has been used for many years to evaluate 
treatment effects in clinical trials for heart failure, pulmo-
nary hypertension and chronic respiratory disease. In 
randomised trials. 6 MW distance increased with cardiac 
resynchronisation therapy, consistent with benefits on 
other clinical outcomes and mortality.13 19 20 However, in 
studies of pharmacological therapies for heart failure, 
there has been no consistent correlation between change 
Table 2 Six-minute walk distance at baseline and change during follow-up for patients randomised to CABG compared with 
medical therapy only (MED)
All patients MED CABG P value
Baseline
  Number 875 466 409
  Mean±SD 340±117 339±116 340±117 0.79
  Median (25th, 75th) 350 (274, 410) 348 (270, 410) 350 (276, 410)
Change at 4 months
  Number 788 420 368
  Mean±SD 33±106 28±102 38±109 0.14
  Median (25th, 75th) 30 (−20, 82) 27 (−22, 77) 35 (−20, 91)
Change at 12 months
  Number 645 331 314
  Mean±SD 41±113 36±114 47±112 0.074
  Median (25th, 75th) 35 (−20, 97) 32 (−25, 75) 40 (−14, 110)
Change at 24 months
  Number 551 287 264
  Mean±SD 33±121 34±113 31±129 0.71
  Median (25th, 75th) 28 (−32, 94) 28 (−26, 94) 27 (−40, 95)
Change at 36 months
  Number 441 220 221
  Mean±SD 0±148 7±139 −7±157 0.48
  Median (25th, 75th) 13 (−56, 75) 20 (−50, 77) 10 (−67, 74)
Six-minute walk distance is in metres.
CABG, coronary artery bypass surgery.
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in 6 MW distance and clinical outcomes.12 19 In an anal-
ysis that included evaluation of 34 heart failure device 
or drug trials, there was a modest statistical correlation 
between the placebo corrected change in 6 MW distance 
and mortality.20 However, 6 MW distance improved 
in only 45% (10 of 22) of studies that evaluated thera-
pies known to have a favourable effect on mortality.20 
Meta-analyses of trials evaluating treatments for pulmo-
nary hypertension have also reported no correlation 
between change in 6 MW distance and treatment effects 
on mortality.12 19 21 The current study suggests that even 
though CABG compared with MED reduces mortality, 
and higher exercise capacity is associated with lower 
mortality, CABG does not improve functional capacity in 
patients with ischaemic LV dysfunction.
COnClusIOn
In patients with ischaemic LV dysfunction and coro-
nary artery disease amenable to CABG, 6 MW distance 
was similar over 3-year follow-up after randomisation 
to CABG or to MED alone. Subgroup analysis did not 
identify patient characteristics associated with a greater 
increase in walk distance after CABG. These observations 
suggest that although CABG is known to improve survival 
over the longer term, it is unlikely to improve exercise 
capacity in most patients with ischaemic LV dysfunction.
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